MariMed Inc. Reports $39.5 Million Revenue in Q1 2026, Driven by Product Sales Growth

MariMed Inc. reported a revenue of $39.5 million for the first quarter of 2026, reflecting a 4.2% increase from $37.9 million in the same period of 2025. The growth was primarily driven by a rise in product sales, particularly in retail and wholesale segments, which saw increases of 4.8% and 4.4%, respectively. Retail sales were bolstered by strong performance in Delaware and Maryland, although some declines were noted in Illinois and Massachusetts. The company's gross profit for the quarter was $15.3 million, with a gross margin of 38.7%, slightly down from 39.8% in the prior year, attributed to higher costs associated with employee and facility expenses.

In terms of operational changes, MariMed completed the acquisition of First State Compassion Center (FSC) on March 1, 2025, which has since been fully integrated into its financial results. The company also underwent a significant restructuring of its Series B Convertible Preferred Stock in February 2026, extinguishing the previous obligation and issuing new promissory notes totaling $8 million. This restructuring resulted in a gain of $0.7 million recognized in the current quarter. The company’s total liabilities increased to $147.7 million as of March 31, 2026, up from $137.8 million at the end of 2025, largely due to the new debt obligations.

MariMed's operational metrics showed a slight decrease in total operating expenses, which fell to $15.2 million from $16 million year-over-year. Notably, bad debt expenses significantly decreased from $1.4 million to $0.1 million, indicating improved credit management. The company’s employee headcount remained stable, and it continues to focus on enhancing its cultivation and processing capabilities to ensure a reliable supply of high-quality products. The company also reported a net loss of $3.8 million for the quarter, an improvement from a net loss of $5.5 million in the prior year.

Looking ahead, MariMed aims to expand its product offerings and geographic footprint, with plans to increase retail store revenue through enhanced customer experiences and strategic marketing initiatives. The company is also monitoring regulatory changes that could impact its operations, particularly the recent classification of certain cannabis products under Schedule III of the Controlled Substances Act, which may allow for more favorable tax treatment in the future. Management remains optimistic about the company’s growth trajectory, supported by its strategic initiatives and market positioning within the cannabis industry.